In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
暂无分享,去创建一个
[1] B. Pugin,et al. Progress in enantioselective catalysis assessed from an industrial point of view , 2005 .
[2] Hans-Jürgen Federsel. Stereoselective Synthesis of Drugs – An Industrial Perspective , 2006 .
[3] S. LaPlante,et al. RCM of tripeptide dienes containing a chiral vinylcyclopropane moiety: impact of different Ru-based catalysts on the stereochemical integrity of the macrocyclic products. , 2005, The Journal of organic chemistry.
[4] Christian Wandrey,et al. Industrial Biocatalysis: Past, Present, and Future , 2000 .
[5] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[6] Fredric Cohen,et al. Macro trends in pharmaceutical innovation , 2005, Nature Reviews Drug Discovery.
[7] K. Prasad,et al. The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions , 2004 .
[8] H -J. Federsel. Drug discoverers -you need us! , 2001, Drug discovery today.
[9] Hans-Jürgen Federsel,et al. Asymmetry on large scale: the roadmap to stereoselective processes , 2005, Nature Reviews Drug Discovery.
[10] Kurt Faber,et al. Biotransformations in Organic Chemistry , 1992 .
[11] P. Preziosi,et al. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? , 2004, Nature Reviews Drug Discovery.
[12] Sean Ekins,et al. Reengineering the pharmaceutical industry by crash-testing molecules. , 2005, Drug discovery today.
[13] Andreas Vogel,et al. Expanding the range of substrate acceptance of enzymes: combinatorial active-site saturation test. , 2005, Angewandte Chemie.
[14] D. Ripin,et al. Survey of GMP Bulk Reactions Run in a Research Facility between 1985 and 2002 , 2005 .
[15] Simon Frantz. 2005 approvals: Safety first , 2006, Nature Reviews Drug Discovery.
[16] J. Bäckvall,et al. Racemisation in asymmetric synthesis. Dynamic kinetic resolution and related processes in enzyme and metal catalysis , 2001 .
[17] Bruce L. Booth,et al. Opinion: Prospects for productivity , 2004, Nature Reviews Drug Discovery.
[18] David J. Triggle,et al. Medicines in the 21st century Or pills, politics, potions, and profits: Where is public policy? , 2003 .
[19] Hans-Jürgen Federsel. The role of process R&D in drug discovery: Evolution of an interface , 2004 .
[20] Esther F. Schmid,et al. Keynote review: Is declining innovation in the pharmaceutical industry a myth? , 2005, Drug discovery today.
[21] Michael M. Ting,et al. The political logic of regulatory error , 2005, Nature Reviews Drug Discovery.
[22] W. Knowles. Asymmetric hydrogenations (Nobel lecture). , 2002, Angewandte Chemie.
[23] H -J. Federsel. Drug discoverers - you need us! - Reply. , 2001, Drug discovery today.
[24] B. D. Vineyard,et al. Catalytic asymmetric hydrogenation , 1972 .
[25] G. Rothenberg,et al. Optimal Heck Cross‐Coupling Catalysis: A Pseudo‐Pharmaceutical Approach , 2003 .
[26] John Andraos,et al. Unification of Reaction Metrics for Green Chemistry: Applications to Reaction Analysis , 2005 .
[27] Federsel. Building bridges from process R&D: from a customer-supplier relationship to full partnership. , 2000, Pharmaceutical science & technology today.
[28] John L. Tucker,et al. Green Chemistry, a Pharmaceutical Perspective , 2006 .
[29] E. Jacobsen,et al. Practical Considerations in Kinetic Resolution Reactions , 2001 .
[30] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[31] Barry M. Trost,et al. Atom Economy—A Challenge for Organic Synthesis: Homogeneous Catalysis Leads the Way , 1995 .
[32] Carl R. Johnson. Biotransformations in the Synthesis of Enantiopure Bioactive Molecules , 1998 .
[33] Hans-Jürgen Federsel. Development of a Process for a Chiral Aminochroman Antidepressant: A Case Story† , 2000 .
[34] P. Anastas,et al. Green Chemistry , 2018, Environmental Science.
[35] Hans-Jürgen Federsel,et al. A guide to drug discovery: Logistics of process R&D: transforming laboratory methods to manufacturing scale , 2003, Nature Reviews Drug Discovery.
[36] J. Mauskopf,et al. A guide to drug discovery: Pricing medicines: theory and practice, challenges and opportunities , 2005, Nature Reviews Drug Discovery.
[37] V. Gewin. Chemistry's evolution , 2006 .
[38] Merrill Goozner,et al. The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .
[39] B. Trost,et al. The atom economy--a search for synthetic efficiency. , 1991, Science.
[40] Jimmy O. DaSilva,et al. Adsorbent Screening for Metal Impurity Removal in Pharmaceutical Process Research , 2005 .
[41] Hans-Ulrich Blaser,et al. Enantioselective catalysis in fine chemicals production. , 2001, Chemical communications.
[42] E. Antman. Inside the FDA: The Business and Politics Behind the Drugs We Take and the Food We Eat , 2005 .
[43] I. Alfonso,et al. Enantioselective enzymatic desymmetrizations in organic synthesis. , 2005, Chemical reviews.
[44] E. Jacobsen,et al. Privileged Chiral Catalysts , 2003, Science.
[45] Roxanne Khamsi. Painkiller verdict shows mistrust of Merck , 2005, Nature.
[46] Biological chemistry: Enzymes in focus , 2005, Nature.
[47] John Potoski,et al. Timely synthetic support for medicinal chemists. , 2005, Drug discovery today.
[48] Hans-Jürgen Federsel. The integration of process R&D in drug discovery--challenges and opportunities. , 2006, Combinatorial chemistry & high throughput screening.
[49] Mark E. Davis,et al. Catalysis for Environmentally Benign Processing , 1994 .
[50] David F. Horrobin,et al. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.
[51] B. Trost. Asymmetric catalysis: an enabling science. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[52] R. Sheldon. Catalysis: The Key to Waste Minimization * , 1997 .
[53] and Peter J. Harrington,et al. Twenty Years of Naproxen Technology , 1997 .
[54] Martin Poirier,et al. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. , 2004, Organic letters.
[55] M. Dickson,et al. Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.
[56] Hans-Jürgen Federsel. Start small, think big — the art of process R&D , 2002, Nature Reviews Drug Discovery.
[57] M. Rawlins. Cutting the cost of drug development? , 2004, Nature Reviews Drug Discovery.
[58] V. Gotor. Biocatalysis Applied to the Preparation of Pharmaceuticals , 2002 .
[59] Carl M. Cohen. A path to improved pharmaceutical productivity , 2003, Nature Reviews Drug Discovery.